Immune Pharmaceuticals (IMNP) Reaches New 1-Year Low at $0.73
Immune Pharmaceuticals Inc (NASDAQ:IMNP) reached a new 52-week low on Friday . The company traded as low as $0.73 and last traded at $0.78, with a volume of 279800 shares trading hands. The stock had previously closed at $0.77.
The company has a debt-to-equity ratio of 3.04, a quick ratio of 0.03 and a current ratio of 0.03.
An institutional investor recently raised its position in Immune Pharmaceuticals stock. Susquehanna International Group LLP grew its position in Immune Pharmaceuticals Inc (NASDAQ:IMNP) by 41.5% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 69,805 shares of the biopharmaceutical company’s stock after buying an additional 20,488 shares during the period. Susquehanna International Group LLP owned 0.69% of Immune Pharmaceuticals worth $215,000 at the end of the most recent reporting period. Institutional investors own 1.63% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Immune Pharmaceuticals (IMNP) Reaches New 1-Year Low at $0.73” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/immune-pharmaceuticals-imnp-reaches-new-1-year-low-at-0-73/1768913.html.
Immune Pharmaceuticals Company Profile
Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.
Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.